China Net Finance News on April 23 Recently, Johnson & Johnson’s pharmaceutical subsidiary in China Xi’an Janssen Pharmaceutical Co., Ltd. (“Xi’an Janssen”) announced that its subsidiary Tenoya (guselkumab injection, English Trade name: TREMFYA, Guselkumab) has been launched in China for moderate to severe plaque psoriasis adult patients who are suitable for systemic treatment.
Tenoa is the world's first approved interleukin 23 (IL-23) inhibitor, which can target and to inhibit IL-23, a cytokine that plays a key role in psoriasis.
Psoriasis, the medical name is psoriasis, is a chronic, relapsing, systemic, inflammatory disease for which there is currently no cure and requires long-term or even lifelong treatment. The prevalence of psoriasis in China is 0.47%, and the total affected population exceeds 6.5 million. A large epidemiological survey in my country shows that 96.4% of psoriasis is the usual type, with a small amount of pus cell type, erythrodermic type and joint type. Common symptoms include erythema, scales , skin inflammation, and are often accompanied by a variety of comorbidities, such as arthritis, cardiovascular disease, thyroid , diabetes, obesity, etc.
According to Professor Zhang Jianzhong from Peking University People's Hospital, psoriasis has been considered a skin disease in the past, which may be related to local metabolism and inflammation of the skin. However, through in-depth research on the pathogenesis of psoriasis in recent decades, the medical community now unanimously believes that psoriasis is an autoimmune disease . The onset of psoriasis has both genetic factors and a series of external factors such as infection, stress, and pregnancy. Shi Xingxiang, founder of the
Psoriasis Patient Mutual Aid Network, said that psoriasis patients have a strong sense of shame. Even if their condition is serious, they are reluctant to proactively inform their family and friends. Instead, they tend to search for information online or seek help from fellow patients. help. As for the current status of psoriasis treatment, there has been a lot of confusion for a long time. "The confusion in treatment reflects the difficulty of treatment. As a lifelong disease, the treatment of psoriasis has always been a worldwide problem. Until the emergence of interleukin biologics last year, the long-standing treatment dilemma was broken."
According to Professor Jin Hongzhong, chief physician of the Department of Dermatology and Venereology of Peking Union Medical College Hospital, biological agents have many advantages over traditional psoriasis treatments. First of all, it is highly effective and has quick results. The drug usually produces obvious effects within two to four weeks, and after three to four months of treatment, 80% to 90% of patients will achieve satisfactory results. Secondly, it lasts a long time. The drug has a longer half-life, so patients need fewer injections and no longer need to frequently travel to and from the hospital for years. A large number of clinical studies have found that after long-term treatment of one to five years, the condition of patients can be maintained at a relatively stable level; and the side effects are small. Traditional drugs can cause great damage to the patient's liver and kidneys, but biological agents have very precise targets and greatly reduce side effects.
Currently, Tenoya has entered China, covering 26 cities including Beijing, Shanghai, Guangzhou, and Shenzhen. At the same time, the Red Cross Foundation of China launched the "Teqi New Life" assistance project for patients with moderate to severe plaque psoriasis, providing Tenoya (Guse Chitumumab Injection) Drug Aid.
(Editor in charge: Du Ding)
